GlassScriptPhysician profile
Kenneth K Tam
NPI 1821081423
$15,289.07
in general payments reported to CMS, 2019-2025
28 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $353 · 2021: $745 · 2022: $1,157 · 2023: $3,685 · 2024: $6,857 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,088 · Travel and Lodging: $4,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,088.38 |
| Travel and Lodging | $4,743.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,931.01 | 2021-2025 | Micra, Selectsecure |
| Abbott Laboratories | $2,986.49 | 2019-2025 | Aveir, Assurity, Gallant |
| Alnylam Pharmaceuticals INC. | $2,147.02 | 2019-2024 | Onpattro |
| Novartis Pharmaceuticals Corporation | $1,173.72 | 2019-2025 | |
| Pfizer INC. | $766.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $708.40 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $619.35 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $535.95 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $412.99 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $401.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.66 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $334.86 | 2019-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $171.06 | 2023-2024 | Optimizer, Optimizer |
| Lantheus Medical Imaging, INC. | $95.86 | 2019 | |
| Novo Nordisk INC | $94.47 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $80.11 | 2024 | Arcalyst |
| Shockwave Medical, INC | $67.85 | 2025 | |
| Amgen INC. | $67.46 | 2019-2023 | Repatha |
| Kiniksa Pharmaceuticals, LTD. | $48.28 | 2022-2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $46.25 | 2023-2025 | |
| Irhythm Technologies, INC. | $41.41 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $33.05 | 2023 | |
| Astellas Pharma US INC | $29.20 | 2019-2022 | |
| Glaxosmithkline, LLC. | $28.76 | 2025 | Arexvy, Shingrix |
| Heartflow, INC. | $24.41 | 2023 | Ffrct |
| Boston Scientific Corporation | $23.25 | 2022 | |
| Scpharmaceuticals INC. | $16.75 | 2024 | |
| Arbor Pharmaceuticals, INC. | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Tam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.